Tranexamic Acid Dosing for Pediatric Patients
For pediatric patients, tranexamic acid should be dosed at 10 mg/kg IV for most indications, with specific adjustments based on clinical context and route of administration.
Intravenous Dosing
Standard Dosing (FDA-Approved)
The FDA-approved dosing for pediatric patients with hemophilia undergoing dental procedures is 10 mg/kg IV as a single dose immediately before tooth extraction, followed by 10 mg/kg IV 3-4 times daily for 2-8 days post-procedure 1. The infusion rate should not exceed 1 mL/minute to avoid hypotension 1.
Trauma and Major Hemorrhage
For pediatric trauma with significant bleeding, administer 15 mg/kg IV loading dose (maximum 1 g) over 10 minutes, followed by 2 mg/kg/hour infusion (maximum 1 g over 8 hours) 2, 3. This must be given within 3 hours of injury—efficacy decreases by 10% for every 15-minute delay, and administration beyond 3 hours may be harmful 3, 4.
Cardiac Surgery
Multiple dosing regimens have been studied in pediatric cardiac surgery. The most effective approach uses a "triple dose" regimen: 10 mg/kg at induction, 10 mg/kg on cardiopulmonary bypass, and 10 mg/kg after protamine 5. Alternatively, a loading dose of 100 mg/kg followed by 10 mg/kg/hour infusion has been used, with 100 mg/kg added to the bypass prime 6.
A more conservative approach based on recent pharmacokinetic data suggests the "10-10-4-4 rule" for infants under 1 year: 10 mg/kg bolus, 10 mg/kg/hour infusion, then 4 mg/kg into bypass prime with reduced infusion to 4 mg/kg/hour after bypass initiation 7. This maintains therapeutic levels (>20 μg/mL) while avoiding excessive peak concentrations that may increase seizure risk.
Postpartum Hemorrhage (Adolescents)
For adolescent patients with postpartum hemorrhage, use 1 g IV over 10 minutes, with a second 1 g dose if bleeding continues after 30 minutes or restarts within 24 hours 4. This applies to clinically diagnosed PPH (>500 mL vaginal delivery, >1000 mL cesarean section).
Oral Dosing
For oral administration, the dose is 25 mg/kg every 8 hours (maximum 1500 mg per dose) for up to 5 days 8. This has been studied primarily for traumatic hyphema in children, where it reduced secondary hemorrhage rates from 10% to 3%.
Topical Dosing
For topical application, use 50 mg/kg in 20 mL saline applied intrapericardially (cardiac surgery) or undiluted 100 mg/mL solution for wound application 9, 10. The combination of low-dose IV (20 mg/kg) plus topical (50 mg/kg intrapericardially) has shown superior outcomes in pediatric cardiac surgery compared to either route alone 9.
Renal Impairment Adjustments
Dose reduction is essential in renal dysfunction 1:
- Serum creatinine 1.36-2.83 mg/dL: 10 mg/kg twice daily
- Serum creatinine 2.83-5.66 mg/dL: 10 mg/kg once daily
- Serum creatinine >5.66 mg/dL: 10 mg/kg every 48 hours OR 5 mg/kg every 24 hours
Critical Considerations
Timing
The therapeutic window is crucial. In trauma, TXA must be administered within 3 hours of injury—preferably within the first 90 minutes 3, 11. Beyond 3 hours, there is no benefit and potential harm from increased thromboembolic risk.
Thromboembolic Risk
While generally safe in pediatric populations, thromboembolic risk increases significantly at cumulative doses ≥4 g (HR 5.33) 11. Avoid concomitant use with prothrombotic agents including Factor IX concentrates and hormonal contraceptives 1.
Route-Specific Cautions
TXA is for IV use only—inadvertent intrathecal administration has caused seizures and cardiac arrhythmias 1, 12. It is contraindicated in subarachnoid hemorrhage due to risk of cerebral edema and infarction 1.
Age-Specific Pharmacokinetics
Neonates and young infants (<2 months) may require higher doses due to altered pharmacokinetics, with some studies suggesting up to 0.06 mg/kg/hour for effective fibrinolysis inhibition 13. However, the standard 10 mg/kg dosing remains appropriate for most pediatric patients when adjusted for weight 6, 7.
The evidence strongly supports weight-based dosing across all pediatric age groups, with children >40 kg dosed as adults 14, 15. Recent pharmacokinetic studies confirm that age affects both distribution and elimination more than weight alone, but weight-based dosing (10 mg/kg) performs well across the pediatric spectrum 6.